(MRVI) Maravai Lifesciences - Ratings and Ratios

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company specializing in products and services that support the development of drug therapies, vaccines, cell and gene therapies, and diagnostics. Operating globally across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America, the company is a key player in enabling advancements in biopharmaceuticals. Maravai operates through two primary segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on manufacturing and supplying products critical to gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This includes reagents for DNA and RNA synthesis, modification, labeling, and purification, as well as messenger RNA, oligonucleotides, CleanCap capping technology, custom enzyme development, and research products for protein labeling and detection. The Biologics Safety Testing segment offers analytical products and services for biologic manufacturing process development, such as custom antibody and assay development, HCP ELISA kits, bioprocess impurity and contaminant detection kits, viral clearance prediction kits, and ancillary reagents. Maravais products address critical stages of biopharmaceutical development, from nucleic acids for diagnostic and therapeutic applications to antibody-based solutions for detecting impurities in production. The company serves biopharmaceutical firms, research institutions, and in vitro diagnostics companies. Founded in 2014 and headquartered in San Diego, California, Maravai is a trusted partner in advancing life sciences innovation.

Based on the provided data, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is currently trading at $2.04 with a 20-day average volume of 1,554,383 shares. The stock is below its 20-day SMA of $1.93 but above its 50-day SMA of $2.30, indicating short-term volatility. The 200-day SMA of $5.73 reflects a longer-term downtrend. The ATR of 0.15 suggests relatively low price movement. Fundamentally, the company has a market cap of $756.22M, a forward P/E of 370.37, and a P/S ratio of 2.92, indicating high valuation expectations despite a negative RoE of -38.17. With no historical P/E, the market is pricing in future growth. The stocks technical and fundamental data suggest a speculative investment profile, with potential upside tied to execution in its core segments and broader biopharmaceutical industry trends.